Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
77,331,078
-
Number of holders
-
217
-
Total 13F shares, excl. options
-
84,318,823
-
Shares change
-
+873,660
-
Total reported value, excl. options
-
$3,385,111,233
-
Value change
-
+$50,758,270
-
Put/Call ratio
-
131%
-
Number of buys
-
98
-
Number of sells
-
-92
-
Price
-
$40.15
Significant Holders of Xenon Pharmaceuticals Inc. - Common Stock (XENE) as of Q3 2025
249 filings reported holding XENE - Xenon Pharmaceuticals Inc. - Common Stock as of Q3 2025.
Xenon Pharmaceuticals Inc. - Common Stock (XENE) has 217 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 84,318,823 shares
.
Largest 10 shareholders include FMR LLC (8,918,907 shares), Avoro Capital Advisors LLC (5,400,000 shares), BlackRock, Inc. (4,770,951 shares), Driehaus Capital Management LLC (4,169,114 shares), JANUS HENDERSON GROUP PLC (3,943,885 shares), WELLINGTON MANAGEMENT GROUP LLP (3,609,857 shares), BRAIDWELL LP (3,605,029 shares), Capital International Investors (3,181,493 shares), Commodore Capital LP (2,700,000 shares), and Polar Capital Holdings Plc (2,546,766 shares).
This table shows the top 217 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.